NSE: GLENMARK · 8 October 2026 · Pre-market update
- Glenmark Pharmaceuticals is in focus after its US subsidiary, Glenmark Therapeutics Inc., announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product targets the over-the-counter dermatology market, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026. Investors will closely watch how this new dispensing option impacts the company's US dermatology portfolio performance after market open.
- Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs to provide a more convenient dispensing option for consumers. The product's active ingredient is comparable to Differin Gel, 0.1%, addressing an OTC market that recorded approximately $45.8 million in annual sales based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management notes that the launch strengthens the growing U.S. dermatology portfolio by offering consumer-focused healthcare solutions.
- Trading volume was 0.91 times the 20-day average daily volume.
Glenmark Pharmaceuticals Company News Before Market Open
Glenmark Pharmaceuticals is in focus after its US subsidiary, Glenmark Therapeutics Inc., announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product targets the over-the-counter dermatology market, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026. Investors will closely watch how this new dispensing option impacts the company's US dermatology portfolio performance after market open.
The launch of Adapalene Gel USP, 0.1% in new pump packs expands Glenmark's US over-the-counter dermatology product offerings. Targeting a segment with approximately $45.8 million in recent annual US market sales highlights potential revenue streams in the consumer health division. The prior session closed up 0.7% at ₹2311.0 on October 6, 2026, providing a baseline technical reference ahead of trading.
4.94 lakh shares traded on 6 October 2026. This compares with a 20-day average daily volume of 5.42 lakh shares (0.91 times). The five-day average daily volume was 8.00 lakh shares.
The launch of Adapalene Gel USP, 0.1% in new pump packs expands Glenmark's US over-the-counter dermatology product offerings. Targeting a segment with approximately $45.8 million in recent annual US market sales highlights potential revenue streams in the consumer health division. The prior session closed up 0.7% at ₹2311.0 on October 6, 2026, providing a baseline technical reference ahead of trading.
Latest Company Developments
Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs to provide a more convenient dispensing option for consumers. The product's active ingredient is comparable to Differin Gel, 0.1%, addressing an OTC market that recorded approximately $45.8 million in annual sales based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management notes that the launch strengthens the growing U.S. dermatology portfolio by offering consumer-focused healthcare solutions.
Expands Glenmark's footprint in the US over-the-counter dermatology sector, offering a new product option in a market with established annual sales.
a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.76% on 30 June 2026. This compares with 16.80% on 31 March 2026, a change of -0.04 percentage points.
The filing reported 37 MF/UTI holders.
What to Watch Next
- Market reaction and trading volume at the open following the announcement of the US product launch.
- Price action relative to the prior session's high of ₹2320.0 and low of ₹277.3.
- Sustained interest in the company's US dermatology portfolio developments.
Other Dated Coverage
- Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026 — 7 October 2026
- Why Glenmark Pharmaceuticals Shares Are Up 0.70% Today | 6 October 2026 — 6 October 2026
- Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026 — 5 October 2026
More Glenmark Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Glenmark Pharmaceuticals company news?
Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs to provide a more convenient dispensing option for consumers. The product's active ingredient is comparable to Differin Gel, 0.1%, addressing an OTC market that recorded approximately $45.8 million in annual sales based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management notes that the launch strengthens the growing U.S. dermatology portfolio by offering consumer-focused healthcare solutions.
How strong was Glenmark Pharmaceuticals’s trading volume?
4.94 lakh shares traded, 0.91 times the 20-day average daily volume. The price and volume data are dated 6 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.